Make your prediction
Buy inPayout
$100
$114
Buy prediction

About

If the FDA's decision on Venglustat by Sanofi in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Venglustat is an oral small-molecule drug developed by Sanofi that works by slowing down the body's production of a fatty substance called glucosylceramide, which builds up to harmful levels in people with Gaucher disease — think of it like adjusting a factory's output dial rather than cleaning up the mess after the fact. It belongs to a class called substrate reduction therapy (SRT), meaning it targets the upstream source of the problem rather than replacing a missing enzyme. Because it is a small molecule taken by mouth and designed to cross into the brain, it has potential to address the neurological symptoms that older enzyme-based treatments cannot reach.

If the FDA's decision on Venglustat by Sanofi in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Venglustat is an oral small-molecule drug developed by Sanofi that works by slowing down the body's production of a fatty substance called glucosylceramide, which builds up to harmful levels in people with Gaucher disease — think of it like adjusting a factory's output dial rather than cleaning up the mess after the fact. It belongs to a class called substrate reduction therapy (SRT), meaning it targets the upstream source of the problem rather than replacing a missing enzyme. Because it is a small molecule taken by mouth and designed to cross into the brain, it has potential to address the neurological symptoms that older enzyme-based treatments cannot reach.

No volume detected, be the first!

Key stats

Expiry
Jan 1, 2027(89 days)
Interest
$1,267.26
Vol (24H)
$124.46→ 0.00%
Total
$1.9K
Timeline & rules

Timeline & payout

This market will close and expire when an outcome occurs. Otherwise, it closes by Jan 1, 2027, 4:59 AM GMT+0.

Trading prohibitions

The following are prohibited from trading this contract:
  • Persons who are employed by any of the Source Agencies are not permitted to trade on the Contract.
  • Persons who hold any material, non-public information on the Underlying are not permitted to trade on the Contract.
Trending markets

A new era of Coinbase has begun

The future of money is here. Be one of the first to get access and try new features the moment they’re available.

Create an account now
FAQs

Discover more

Legal
Prediction markets are offered by Coinbase Financial Markets, a registered futures commission merchant with the Commodity Futures Trading Commission and a Member of the National Futures Association. Trading prediction contracts involve substantial risk and may result in the loss of your entire investment. Contracts pay out only if the specified event occurs. Trade only if you understand the product and believe it is appropriate for your financial situation and objectives.Certain content has been prepared by third parties not affiliated with Coinbase Financial Markets or any of its affiliates and Coinbase is not responsible for such content. Coinbase is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Information is provided for informational purposes only and is not investment advice. This is not a recommendation to buy or sell a particular digital asset or to employ a particular investment strategy. Coinbase makes no representation on the accuracy, suitability, or validity of any information provided or for a particular asset. Prices shown are for illustrative purposes only. Actual cryptocurrency prices and associated stats may vary. Data presented may reflect assets traded on Coinbase’s exchange and select other cryptocurrency exchanges. Past performance is not a reliable indicator of future results.